Ironwood Pharmaceuticals (IRWD) Depreciation & Amortization (CF) (2010 - 2026)

Ironwood Pharmaceuticals has reported Depreciation & Amortization (CF) for 17 years, with the latest figure at $443000.0 in Q1 2026.

• Quarterly Depreciation & Amortization (CF) fell 7.52% year-over-year to $443000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $1.8 million (down 6.68% YoY) and the FY2025 annual result came in at $1.1 million, down 8.33% from the prior year.
• Depreciation & Amortization (CF) fell to $443000.0 in Q1 2026 per IRWD's latest filing, from $460000.0 in the prior quarter.
• Over five years, Depreciation & Amortization (CF) peaked at $513000.0 in Q1 2024 and troughed at $270000.0 in Q2 2023.
• A 5-year average of $431058.8 and a median of $467000.0 in 2025 frame the typical range for Depreciation & Amortization (CF).
• The sharpest annual moves came in 2023 and 2024: Depreciation & Amortization (CF) slipped 25.0% in 2023, then surged 87.41% in 2024.
• Over 5 years, Depreciation & Amortization (CF) stood at $340000.0 in 2022, then surged by 50.59% to $512000.0 in 2023, then decreased by 5.27% to $485000.0 in 2024, then retreated by 5.15% to $460000.0 in 2025, then decreased by 3.7% to $443000.0 in 2026.
• According to Business Quant data, Depreciation & Amortization (CF) over the past three periods registered $443000.0, $460000.0, and $475000.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.